FDA Approves Adcetris With Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma

The FDA has approved brentuximab vedotin (Adcetris, Seagen, a subsidiary of Pfizer) in combination with ...

FEBRUARY 19, 2025

In Advanced Hodgkin Lymphoma, New 6-Drug Regimen Exceeds Standard for Efficacy, Tolerability

A phase 3 randomized trial has shown that compared with BEACOPP, a standard seven-drug regimen for classic advanced ...

JUNE 26, 2024

Nivolumab Substituted for Brentuximab Vedotin in Hodgkin Therapy Improves Outcomes

In older patients with advanced-stage classic Hodgkin lymphoma (cHL), outcomes are particularly improved with lower ...

FEBRUARY 21, 2024

ECHELON-1: BV + Chemo New First-Line Standard for Advanced cHL

Brentuximab vedotin combined with AVD chemotherapy is the first regimen to demonstrate improved OS versus ...

DECEMBER 7, 2022

Adcetris Gets New Indication

The FDA approved brentuximab vedotin (Adcetris, Seagen) for the treatment of pediatric patients aged 2 years and ...

NOVEMBER 16, 2022

Brentuximab Vedotin Improves Overall Survival in Stage III, IV Hodgkin Lymphoma

A new study has confirmed the superiority of brentuximab vedotin (Adcetris, Seagen) plus doxorubicin, vinblastine ...

SEPTEMBER 7, 2022

ECHELON-2 Data Support Brentuximab Combination Rx for PTCL

San Diego—Last fall, brentuximab vedotin (BV) was approved as part of a combination for the first-line ...

MAY 1, 2019

Adcetris Now Indicated to Treat Classic Hodgkin Lymphoma

The FDA approved brentuximab vedotin (Adcetris, Seattle Genetics) in combination with chemotherapy for the ...

MARCH 22, 2018

Adcetris Approved To Treat Most Common Cutaneous Lymphomas

The FDA granted approval to brentuximab vedotin (Adcetris, Seattle Genetics) for the treatment of adults with ...

NOVEMBER 9, 2017

BV + Bendamustine May Be Effective for Primary Refractory HL

The combination of brentuximab vedotin and bendamustine may be effective in inducing complete remission in patients ...

JUNE 13, 2017

Brentuximab Vedotin Beats Standard of Care for CTCL

The CD30-targeted antibody–drug conjugate brentuximab vedotin (BV) was far more active than current ...

MARCH 15, 2017